Results 111 to 120 of about 221,455 (333)

Rituximab en glomeruloesclerosis focal y segmentaria [PDF]

, 2016
Introducción: El síndrome nefrótico es un trastorno renal multifactorial. Es la manifestación clínica de las alteraciones bioquímicas producidas por una lesión glomerular que altera la permeabilidad de la pared capilar glomerular.
Velasco Paredes, Margarita Maria, Urrego Lozano, Ntalia, Vacca Orrego, Luisa Maria, Pedraza García, Nedier, Salcedo Libreros, Luis Felipe   +4 more
core   +1 more source

Ofatumumab Therapy and Long‐Term Seizure Outcomes of Patients With Relapsing Anti‐NMDA Receptor Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There is a lack of studies on seizure outcomes associated with ofatumumab therapy in patients for relapsing anti‐N‐methyl‐D‐aspartate (NMDA) receptor encephalitis. We aimed to evaluate long‐term seizure outcomes of ofatumumab therapy for relapsing anti‐NMDA receptor encephalitis.
Jian Wang, Mengjiao Li, Ping Kong
wiley   +1 more source

Rituximab in childhood steroid-dependent nephrotic syndrome: a single-center experience

Egyptian Pediatric Association Gazette
Background Most children with idiopathic nephrotic syndrome are steroid-sensitive. However, the majority of them relapse. Unfortunately, 50–70% of relapsers will develop frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome ...
Shrouq Badr, Mahmoud Mohi El-Din El-Kersh, Samar Atef Elshafey, Nancy Abdel-Salam   +3 more
doaj   +1 more source

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Journal of Clinical Oncology, 2019
PURPOSE The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia.
A. Kater, J. Seymour, P. Hillmen, B. Eichhorst, A. Langerak, C. Owen, M. Verdugo, J. Wu, E. Punnoose, Yan-Wen Jiang, Jue Wang, M. Boyer, K. Humphrey, M. Mobasher, T. Kipps   +14 more
semanticscholar   +1 more source

Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement [PDF]

, 2014
Secondary antibody deficiency can occur as a result of haematological malignancies or certain medications, but not much is known about the clinical and immunological features of this group of patients as a whole. Here we describe a cohort of 167 patients
Matthew Buckland (589995), Lorena Lorenzo (589997), Matthew Buckland, Dempster, J, Duraisingham Sai S., Longhurst Hilary J., Matthew Buckl, Sai S. Duraisingham, Sofia Grigoriadou (589998), Sai S Duraisingham, Hilary J Longhurst, John Dempster, Dempster John, Grigoriadou Sofia, Duraisingham, SS, Lorenzo, L, Buckland Matthew, Grigoriadou, S, Sofia Grigoriadou, Lorenzo Lorena, Sai S. Duraisingham (589994), Buckland, M, Longhurst, HJ, Lorena Lorenzo, John Dempster (589996), Hilary J. Longhurst (589999), Hilary J. Longhurst   +26 more
core   +2 more sources

Copine‐4 Paraneoplastic Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT We characterize copine‐4 (CPNE4)‐IgG and report clinical associations. Among 844 samples with unclassified neural IgGs identified by mouse‐brain indirect immunofluorescence assay over 2 years, 5 samples (serum, 3; CSF, 2) from 3 patients produced a distinctive cerebrum‐restricted synaptic pattern.
Mimi S. Fang, Amy Ml Quek, Clement Yong, Amir Adeli, Gabrielle N. Conway, Connie E. Lesnick, Diana Anissian, Divyanshu Dubey, John R. Mills, Sean J. Pittock, Anastasia Zekeridou, Michael Gilligan, Andrew McKeon   +12 more
wiley   +1 more source

Investigation of Complement Activation and Cytokine Signatures in AQP4+ NMOSD, MOGAD, and MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Aquaporin‐4‐IgG seropositive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), and multiple sclerosis (MS) are pathophysiologically distinct neuroinflammatory disorders. Complement activation is a major mechanism of injury in AQP4+ NMOSD, whereas its role in
Angeliki G. Filippatou, Susana Dominguez‐Penuela, David Acero‐Garces, Georgios Gakis, Matthew D. Smith, Yasmin Resto, Maria Reyes‐Mantilla, Haiwen Chen, Isabella Hernandez, Yana Said, Andrea Salazar‐Camelo, Christina Huynh, Alessia Tassoni, Ted Yednock, Rick Artis, Yaisa Andrews‐Zwilling, Scott D. Newsome, Shiv Saidha, Pavan Bhargava, Ellen M. Mowry, Kathryn C. Fitzgerald, Peter A. Calabresi, Carlos A. Pardo, Elias S. Sotirchos   +23 more
wiley   +1 more source

Tumor uptake on ⁸⁹Zr-rituximab-PET, discordant with CD20 expression in biopsy.

, 2017
Axial images, from left to right attenuation corrected PET, low dose CT and fused PET/CT image of patient 6. a) 89Zr-rituximab-PET shows tumor uptake discordant with a CD20-negative biopsy (axillar lymph node).
Guus A. M. S. van Dongen (506975), Daphne de Jong (3622187), Danielle J. Vugts (506973), Otto S. Hoekstra (300973), Yvonne W. S. Jauw (3622184), Josée M. Zijlstra (3622181), Sonja Zweegman (482354), Marc C. Huisman (3622178)   +7 more
core   +1 more source

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

, 2022
PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström’s macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE.
Varettoni, M, Tam, CS, Buske, C, Herbaux, C, Leblond, V, MacDonald, D, Treon, SP, Arango-Hisijara, I, Trotman, J, Palomba, ML, Shustik, C, Garcia-Sanz, R, Mahe, B, Heffner, LT, Tedeschi, A, Hauns, B, Dimopoulos, MA, Kastritis, E, Ping, J, Matous, JV   +19 more
core   +1 more source

Serostatus‐Specific Prognostic Profiles and Phenotype‐Dependent Therapeutic Windows in Autoimmune Encephalitis: A Multicenter Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background While autoimmune encephalitis (AE) outcomes vary, serostatus‐specific prognostic determinants and institutional clustering effects remain poorly characterized. We aimed to delineate the distinct prognostic architecture of AE, identifying serostatus‐specific risk factors and potential therapeutic windows.
Xiaohong Tang, Jingxian Wang, Kaixin Zhu, Zhen Zhang, Liao Wu, Wei Wang, Chang Li, Qingyun Li, Hao Li, Jinghua Chen, Zhangxu Lian, Bin Liu, Tengfei Liu, Chunmei Wen, Nuan Wang, Sen Qun, Lishun Xiao, Qingwei Lai   +17 more
wiley   +1 more source